Valneva SE

Valneva SE (VALN) priced its initial public offering on May 7, 2021 at $26.41 per ADS, within its $24.04–$28.85 range, raising $93.5M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $1.29B. Goldman Sachs was lead-left underwriter, joined by Jefferies, Guggenheim and Garnier. Cooley and Hogan Lovells advised the company and Goodwin Procter advised the underwriters.

Valneva SE is a specialty vaccine company that develops and commercializes prophylactic vaccines for infectious diseases with significant unmet medical need. It targets diseases that lack a preventive vaccine and has commercialized two vaccines.

Status

IPO

Ticker

VALN

Exchange

Nasdaq Global Select

Priced

May 7, 2021

IPO price

$26.41 per ADS

Price range

$24.04–$28.85

Raised

$93.5M

Market cap at IPO price

$1.29B

First filed

Apr 9, 2021

Underwriters

Goldman Sachs, Jefferies, Guggenheim and Garnier

Company counsel

Cooley and Hogan Lovells

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

France

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.